JPRN-UMIN000000609已完成2 期
Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Patients - Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Patients
Japan Breast Cancer Research Network0 个研究点目标入组 130 人开始时间: 2007年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) Patients with synchronous multiple cancers (2) Complicated with infection (3) Fever from suspected infection (4) Metastasis to the central nerve system (5) A history of ischemic cardiac diseases (6) Active gastrointestinal ulcer (7) Severe nerve disorder (8) Women who are potentially pregnant, pregnant, or breast-feeding (9) Severe drug allergy (10) Severe suppression of the bone marrow (11) Severe renal disorder (12) Being treated with other pyrimidine fluoride antineoplastic agents (including any combination therapy) (13) Being treated with flucytosine (14) Complicated with the infection onset which a study doctor assesses to be inappropriate for this study
研究者
相似试验
已完成
2 期
Capecitabine vs. S-1 in Unresectable or Recurrent Breast CancerBreast NeoplasmsNCT00438100Japan Breast Cancer Research Network142
已完成
不适用
Randomised phase II study comparing capecitabine with oral cyclophosphamide and capecitabine in patients with advanced breast cancerAdvanced breast cancerCancerBreast cancerISRCTN68662102Cancer Trials New Zealand (CTNZ) (New Zealand)82
已完成
不适用
A randomized controlled trial comparing capecitabine 5-days-on/2-days-off regimen with conventional regimen in stage II and III colorectal cancer.StageII(high risk) and stageIII resectable colorectal cancerJPRN-UMIN000032865Wakayama Medical University110
进行中（未招募）
不适用
Tesetaxel, an oral taxane, and capecitabine versus placebo and capecitabine in gastric cancerHistologically or cytologically confirmed gastric carcinoma, including gastric or gastroesophageal-junction adenocarcinomaMedDRA version: 14.1Level: LLTClassification code 10017760Term: Gastric cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022164-12-DEGenta Incorporated580
已完成
不适用
Phase I/II Study of Capecitabine in Combination with Peginterferon Alfa-2a for Patients with Advanced Hepatocellular CarcinomaHepatocellular CarcinomaJPRN-UMIN000005697Chiba University Hospital42